A detailed history of Morgan Stanley transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,357,506 shares of TSVT stock, worth $18.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,357,506
Previous 4,842,810 10.02%
Holding current value
$18.4 Million
Previous $20.7 Million 12.74%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.09 - $6.0 $1.5 Million - $2.91 Million
-485,304 Reduced 10.02%
4,357,506 $23.3 Million
Q4 2023

Feb 13, 2024

BUY
$1.57 - $4.58 $5.48 Million - $16 Million
3,489,494 Added 257.85%
4,842,810 $20.7 Million
Q3 2023

Nov 15, 2023

BUY
$3.14 - $11.2 $1.81 Million - $6.45 Million
576,195 Added 74.14%
1,353,316 $5.3 Million
Q2 2023

Aug 14, 2023

SELL
$8.45 - $12.48 $3.28 Million - $4.84 Million
-388,205 Reduced 33.31%
777,121 $7.86 Million
Q1 2023

May 15, 2023

BUY
$9.21 - $14.98 $8.77 Million - $14.3 Million
952,227 Added 446.85%
1,165,326 $11.9 Million
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $1.33 Million - $2.63 Million
154,808 Added 265.58%
213,099 $2 Million
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $1.91 Million - $2.67 Million
-152,430 Reduced 72.34%
58,291 $849,000
Q2 2022

Oct 27, 2022

SELL
$10.55 - $18.81 $1.98 Million - $3.53 Million
-187,683 Reduced 47.11%
210,721 $2.78 Million
Q2 2022

Aug 15, 2022

SELL
$10.55 - $18.81 $1.98 Million - $3.53 Million
-187,683 Reduced 47.11%
210,721 $2.78 Million
Q1 2022

Oct 27, 2022

BUY
$11.67 - $26.72 $2.19 Million - $5.01 Million
187,683 Added 89.07%
398,404 $6.8 Million
Q1 2022

May 13, 2022

BUY
$11.67 - $26.72 $3.29 Million - $7.54 Million
282,046 Added 242.4%
398,404 $6.8 Million
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $1.6 Million - $4.95 Million
116,358 New
116,358 $2.98 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $160M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.